Lung cancer is the leading cause of cancer deaths worldwide. Despite never smokers
comprising between 10 and 25% of all cases, lung cancer in never smokers (LCNS) is …

Introduction Low-dose computed tomography (LDCT) screening reduces lung cancer
mortality, but current eligibility criteria underestimate risk in women and racial minorities. We …

Rapid advancements in high-throughput biological techniques have facilitated the
generation of high-dimensional omics datasets, which have provided a solid foundation for …

Although GWASs have been conducted to investigate genetic variation of bladder
tumorigenesis, little is known about genetic interactions that may influence bladder cancer …

Background A reliable risk prediction model is critically important for identifying individuals
with high risk of developing lung cancer as candidates for low-dose chest computed …

Background: Clinical, molecular, and genetic epidemiology studies displayed remarkable
differences between ever-and never-smoking lung cancer. Methods: We conducted a …

Epigenome‐wide gene–gene (G× G) interactions associated with non‐small‐cell lung
cancer (NSCLC) survival may provide insights into molecular mechanisms and therapeutic …

DNA methylation serves as a reversible and prognostic biomarker for oral squamous cell
carcinoma (OSCC) patients. It is unclear whether the effect of DNA methylation on OSCC …

Plasma proteins are promising biomarkers and potential drug targets in lung cancer. To
evaluate the causal association between plasma proteins and lung cancer, we performed …

Background The homologous recombination (HR) repair pathway for DNA damage,
particularly the BRCA1 and BRCA2 genes, has become a target for cancer therapy, with …